首页|期刊导航|中华医学杂志（英文版）|First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer:a cost-effectiveness analysis from China
中华医学杂志（英文版）2019，Vol.132Issue(23)：2790-2794,5.DOI:10.1097/CM9.0000000000000536
First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer:a cost-effectiveness analysis from China
First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer:a cost-effectiveness analysis from China
摘要
关键词
Cost-effectiveness/Immunotherapy/Chemotherapy/Small cell lung cancerKey words
Cost-effectiveness/Immunotherapy/Chemotherapy/Small cell lung cancer引用本文复制引用
Ling-Yu Li,Hong Wang,Xiao Chen,Wen-Qian Li,Jiu-Wei Cui..First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer:a cost-effectiveness analysis from China[J].中华医学杂志（英文版）,2019,132(23):2790-2794,5.基金项目
This work was supported by Research on Chronic Noncommunicable Diseases Prevention and Control of National Ministry of Science and Technology (2016YFC1303804) （2016YFC1303804）
the National Natural Science Foun-dation of China (81802487),China Postdoctoral Founda-tion Project (2019M651217),and Youth Development Foundation of the First Hospital of Jilin University (JDYY92018028) （81802487）
the National Natural Science Founda-tion of China (81500116). （81500116）
